The revision of Annex 15 of the European GMP (Qualification and Validation) represents a significant change in the evolution of pharmaceutical quality systems. The main objective of the update is to reinforce the qualification and validation requirements, incorporating lessons learned following the nitrosamine crisis and aligning regulatory expectations with the quality risk management principles defined in ICH Q9(R1).
Although the review is primarily aimed at the pharmaceutical industry, its effects will likely extend beyond the manufacture of medicines for human use, also reaching manufacturers of active ingredients (API), veterinary medicines and, indirectly, to certain cosmetic sectors that operate under advanced GMP standards.
The review has two main objectives:
- Formally extend the scope of Annex 15 to manufacturers of active substances (APIs), both chemical and biological.
- Align qualification and validation requirements with the risk management principles established in ICH Q9(R1).
The main change: from optional guidance to effective requirement for API manufacturers
The most relevant modification planned is that Annex 15 stops being an optional complementary guide for manufacturers of active substances and becomes a verifiable compliance reference during European GMP and PIC/S inspections. In other words, it will be an inspectable requirement.
This decision comes after investigations carried out during the nitrosamine crisis, where inspectors identified deficiencies related to:
- Insufficient knowledge of the process.
- Inadequate control strategies.
- Poor investigation of deviations.
- Insufficient pollution controls.
- Weaknesses in validation and change control activities.
For API plants, this will most likely mean:
- Greater documentary requirement.
- More in-depth reviews of Validation Master Plans.
- Reinforcement of process validation.
- Greater supervision of outsourced activities.
- More robust and traceable risk justifications.
Expected impact on API plants
Strengthening the life cycle approach
API manufacturers must demonstrate that validation is not a one-time exercise, but an activity maintained throughout the life cycle of the product and the process.
This will involve greater use of historical data, periodic reviews of validated status, continuous evaluation of trends, and a closer relationship between changes, risks, and validation.
Recovery of solvents and materials
The review proposes paying special attention to the processes of recovery of materials and solvents, an especially relevant aspect in the production of chemical APIs.
Companies must demonstrate more clearly:
- The consistency of the recovery process.
- The absence of cross contamination.
- The equivalence of quality with respect to virgin materials.
Greater supervision of suppliers and third parties
Validation activities carried out by suppliers, external laboratories or specialized engineering will be subject to heightened scrutiny.
The trend points towards:
- More detailed technical contracts.
- Specific validation audits.
- Critical review of protocols and reports issued by third parties.
Impact on the veterinary industry
Although Annex 15 has been part of the GMP framework applicable to veterinary medicines in Europe for years, the future revision will probably have a significant impact on the way veterinary manufacturers design, justify and maintain their qualification and validation activities. Annex 15 itself already applies to veterinary medicines along with those for human use, so any modification will be directly applicable to this sector.
Greater alignment with human medicine standards
In recent years, a regulatory trend has been observed towards the harmonization of quality requirements between human and veterinary medicines. The revision of Annex 15 reinforces this direction by introduce clearer expectations on risk management, validation life cycle and process knowledge.
For many veterinary companies this will not necessarily mean the creation of new systems, but rather the need to demonstrate with greater scientific rigor that existing systems are effective.
Inspectors will likely pay more attention to things like:
- Scientific justification of the acceptance criteria.
- Management of deviations during validation activities.
- Periodic review of validated status.
- Relationship between risk analysis and control strategy.
- Evidence of knowledge of the process and product.
Products with high variability and small volumes
A particularity of the veterinary industry is the great diversity of species, dose, shapes pharmaceutical and sizes of lot.
Many companies work with relatively small commercial batches, multi-species products, seasonal manufacturing and infrequent production campaigns.
In this context, the practical application of life cycle-based validation principles can represent a significant challenge. It will be necessary to justify with data when a revalidation is necessary and when can be replaced by monitoring continues or periodic risk-based reviews. The further integration of ICH Q9(R1) envisaged in the Annex 15 revision points precisely towards this scientific and risk-proportionate approach.
Impact on the manufacturing of veterinary biological products
One of the segments that could be most affected is veterinary vaccines and others biological products.
In these facilities, authorities usually pay special attention to:
- Qualification of critical equipment.
- Validation of aseptic systems.
- Environmental monitoring.
- Computerized systems.
- Traceability of biological materials.
The revision of Annex 15 could boost more robust validation strategies and closer integration between Production, Quality and Engineering departments, especially when using advanced technologies or complex processes.
Transportation and supply chain
Another area that is especially relevant for veterinary manufacturers is distribution.
The concept paper mentions a greater integration of GDP related aspects, including strengthened requirements for transportation verification and validation. This may particularly affect temperature-sensitive products, vaccines and veterinary biological medicines that are distributed to extensive networks of clinics, distributors and livestock cooperatives.
Consequently, we can expect more thermal mapping studies, greater packaging qualification, review of distribution routes, and increased monitoring of transport conditions.
And what will happen to the cosmetics industry?
From a strictly regulatory point of view, the revision of Annex 15 does not directly affect cosmetic manufacturers, since they operate under Regulation (EC) 1223/2009 and the ISO 22716 standard, not under pharmaceutical GMP. However, it would be a mistake to conclude that the cosmetics sector will remain completely unaffected by these changes.
Industrial reality shows that many of the regulatory trends born in the pharmaceutical sector end up transferring, partially or totally, to cosmetics, especially in multinational companies and highly technically demanding manufacturers.
Convergence towards more robust GMP models
The cosmetics market has evolved significantly over the last decade.
Consumers and authorities increasingly demand traceability, consistency between batches, contamination control, objective evidence of quality and adequate change management.
As a result, many cosmetic organizations already use concepts from the pharmaceutical environment, although they are not legally required to do so.
The future review of Annex 15 may accelerate this trend, especially in companies that already work on integrated quality systems, shared equipment with pharmaceutical production, third-party manufacturing and highly regulated international markets.
Hybrid manufacturers: the most affected group
Companies that simultaneously manufacture medicines, health products, dietary supplements and cosmetics will likely be the most impacted.
In these groups there is usually a single corporate quality department responsible for validations, qualifications, calibrations, data integrity and risk management.
When the pharmaceutical area adopts the new requirements of Annex 15, it is foreseeable that many organizations will extend these same criteria to the cosmetic business to simplify procedures, training, internal audits and supervision corporate.
Greater demand in cleaning and prevention of cross contamination
Although cosmetics generally present a different risk profile than medicines, microbiological, chemical or allergenic contamination remains a relevant concern.
The strengthened validation and risk management principles incorporated into the new Annex 15 could influence:
- Cleaning validations.
- Recovery studies.
- Definition of acceptance limits.
- Monitoring programs.
- Evaluation of product changes.
This will be especially relevant for manufacturers of children's cosmetics, products for sensitive skin, cosmeceuticals, products with biotechnological ingredients as well as dermatological lines close to the pharmaceutical field.
Digitization and validation of computerized systems
A trend parallel to the revision of Annex 15 is the digital transformation of industrial operations.
Although the formal validation of computerized systems is a fundamentally pharmaceutical requirement, more and more cosmetic companies are implementing:
- MES (Manufacturing Execution Systems).
- Electronic document management systems.
- Sistemas LIMS.
- Serialization and traceability tools.
Regulatory pressure on the pharmaceutical sector is usually subsequently transferred to the Audit, certification and good practices expectations in cosmetics. Therefore, many organizations will take advantage of the review of Annex 15 to also update their digital governance models.
A more strategic than regulatory influence
Unlike the API or veterinary sector, the impact on cosmetics will not come from a direct legal obligation. Its impact will be mainly corporate, technical, operational and cultural.
More advanced cosmetic companies will likely use the Annex 15 revision as a reference for strengthen your quality systems and approach standards of excellence increasingly demanding industries.
Conclusion
The future revision of Annex 15 does not seem aimed at introducing a regulatory revolution, but rather at raising the level of maturity of validation and qualification systems, especially in the active substances sector. The most important change will be the effective extension of its requirements to API manufacturers, closing a regulatory gap identified after the nitrosamine crisis.
For veterinary plants, the consequence will be greater integration of risk management and the life cycle approach. For the cosmetics industry, although the impact will not be direct regulatory, a significant influence can be expected through the convergence of quality standards and the expectations of multinational groups and highly regulated markets.
In short, companies that begin now to strengthen their validation systems, process knowledge and Quality Risk Management will be better positioned to face future regulatory demands and next-generation inspections.
Turn regulatory change into a competitive advantage
Beyond compliance, the review of Annex 15 represents an opportunity to reinforce knowledge of the process, improve operational robustness and increase the confidence of clients and regulatory authorities. Contact our experts in GMP, validation and qualification to identify priority actions that will allow your organization to successfully adapt to the new regulatory scenario.